UC-II™ is a novel, undenatured (intact) form of type II collagen—the major galactose (sugar) containing protein found in joint and connective tissue. Small doses of undenatured type II collagen have been shown to deactivate killer T-cell attack of joint cartilage in humans, and a preliminary study reported that UC-II™ improved arthritic symptoms in older women. To evaluate the effectiveness and safety of UC-II™ in arthritic dogs, animals were given either 1 mg or 10 mg of the undenatured cartilage daily for 90 days. A third group served as controls. Lameness and pain were evaluated daily during treatment, and for another 30 days after treatment stopped. Both doses of UC-II™ reduced pain and lameness, and were well tolerated. Greater improvements were seen with the higher dose, and as time progressed. Complete symptom recovery was observed in one dog receiving the 10 mg dose. Cytokines, the small secreted proteins which affect immunity and inflammation, were measured in blood samples from the animals. Levels of pro-inflammatory IL-1β were low, while IL-10 levels were elevated. IL-10 is believed to inhibit cytokine production. Arthritic symptoms had returned when the animals were examined 30 days after UC-II™ was discontinued, lending support to the effectiveness of UC-II™. These findings suggest that dietary supplements of UC-II™ may be of potential benefit to those with the signs and symptoms of arthritis.

Source: Bagchi D, DeParle L, Gupta R, Goad J, Canerdy T, Bagchi M, Therapeutic Efficacy and Safety of UC-II (Type II Undenatured Cartilage Derivative) in Arthritic Dogs,10th International Congress of Toxicology-Finland 197:abs. 880, July 2004.